Abstract
Risankizumab (Skyrizi((R))), a humanised IgG monoclonal antibody that targets the p19 subunit of IL-23, was developed by AbbVie in collaboration with ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
